Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 19, 2025
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
GlobeNewswire
·
March 19, 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet …
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies
GlobeNewswire
·
March 19, 2025
HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is …
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
GlobeNewswire
·
March 19, 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other …
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire
·
March 19, 2025
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean …
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire
·
March 19, 2025
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean …
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
GlobeNewswire
·
March 19, 2025
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a …
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
GlobeNewswire
·
March 19, 2025
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of…
GlobeNewswire
·
March 19, 2025
DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s …
Cronos Appoints Anna Shlimak as Chief Financial Officer
GlobeNewswire
·
March 19, 2025
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. …
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
GlobeNewswire
·
March 19, 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
GlobeNewswire
·
March 19, 2025
New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D Specialty Plasma Collected will Support the …
Auron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial Officer
GlobeNewswire
·
March 19, 2025
NEWTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced the appointment of Glenn Goddard …
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
GlobeNewswire
·
March 19, 2025
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and …
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
GlobeNewswire
·
March 19, 2025
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject …
Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements
GlobeNewswire
·
March 19, 2025
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly …
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
GlobeNewswire
·
March 19, 2025
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief …
XORTX Announces Update for Discussion with the FDA
GlobeNewswire
·
March 19, 2025
● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical …
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
GlobeNewswire
·
March 19, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial results for the year ended December 31, 2024 and provides …
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 19, 2025
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in …
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
GlobeNewswire
·
March 19, 2025
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug ( …